198 related articles for article (PubMed ID: 15014552)
21. [Prostaglandin E1 in erectile dysfunction].
Porst H
Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
[TBL] [Abstract][Full Text] [Related]
22. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
[TBL] [Abstract][Full Text] [Related]
23. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
[TBL] [Abstract][Full Text] [Related]
24. [Endocavernous drug infusions revisited].
Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
Kim SC; Seo KK; Park BD; Lee SW
Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
[TBL] [Abstract][Full Text] [Related]
26. Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound.
Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B
J Urol; 2011 Jul; 186(1):228-32. PubMed ID: 21575959
[TBL] [Abstract][Full Text] [Related]
27. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.
Shamloul R; Atteya A; Elnashaar A; Gadallah A; Zohdy W; Abdelsalam W
J Sex Med; 2005 Jan; 2(1):117-20. PubMed ID: 16422914
[TBL] [Abstract][Full Text] [Related]
28. Intracavernous vasoactive pharmacotherapy: the impact of a new self-injection device.
Montorsi F; Guazzoni G; Bergamaschi F; Orlandini A; Da Pozzo L; Barbieri L; Rigatti P
J Urol; 1993 Dec; 150(6):1829-32. PubMed ID: 7693979
[TBL] [Abstract][Full Text] [Related]
29. The value of sildenafil as mode of stimulation in pharmaco-penile duplex ultrasonography.
Speel TG; Bleumer I; Diemont WL; van der Maas MC; Wijkstra H; Meuleman EJ
Int J Impot Res; 2001 Aug; 13(4):189-91. PubMed ID: 11494073
[TBL] [Abstract][Full Text] [Related]
30. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
[TBL] [Abstract][Full Text] [Related]
31. [Intracavernous infusion of drugs].
Bellorofonte C; Dell'Acqua S; Ruoppolo M; Zaatar C; Tombolini P
Arch Ital Urol Nefrol Androl; 1992 Sep; 64(3):251-4. PubMed ID: 1439852
[TBL] [Abstract][Full Text] [Related]
32. Intracavernous drug delivery system: an alternative to intracavernous injection in the treatment of impotence?
Stief CG; Wetterauer U; Kulvelis F; Popken G; Staubesand J; Sommerkamp H
Urol Int; 1990; 45(6):321-5. PubMed ID: 2288047
[TBL] [Abstract][Full Text] [Related]
33. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
von Heyden B; Donatucci CF; Kaula N; Lue TF
J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
[TBL] [Abstract][Full Text] [Related]
34. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
[TBL] [Abstract][Full Text] [Related]
35. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
Wyndaele JJ; de Meyer JM; de Sy WA; Claessens H
Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
[TBL] [Abstract][Full Text] [Related]
36. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
[TBL] [Abstract][Full Text] [Related]
37. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
[TBL] [Abstract][Full Text] [Related]
38. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
39. Erectile dysfunction: intracavernous treatment.
Ledda A
Curr Med Res Opin; 2000; 16 Suppl 1():s59-62. PubMed ID: 11329824
[TBL] [Abstract][Full Text] [Related]
40. Intracorporeal needle breakage as an unusual complication of intracavernous self-injection.
Iacono F; Barra S
Tech Urol; 1998 Mar; 4(1):54-5. PubMed ID: 9568779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
